EGFR and non-small cell lung carcinoma: While first-line ICI monotherapy and ICI + EGFR TKI combination therapy in EGFRm NSCLC patients has thus far been disappointing, intriguing results have been obtained from trials of second-line ICI therapy combinations and multiple open research questions are under clinical investigation (Table 3).